MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells

Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic stem/progenitor cells that is caused by the Bcr-Abl oncoprotein. Clinical resistance to the Bcr-Abl inhibitor imatinib is a critical problem in treating CML. This study investigated the antitumor effect and mechanism of MPT0B169, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Shuit-Mun, Liu, Fu-Hwa, Lee, Yueh-Lun, Huang, Huei-Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729476/
https://www.ncbi.nlm.nih.gov/pubmed/26815740
http://dx.doi.org/10.1371/journal.pone.0148093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729476/
https://www.ncbi.nlm.nih.gov/pubmed/26815740
http://dx.doi.org/10.1371/journal.pone.0148093

Ejemplares similares